# RAD001 and AV-951 in Patients With Refractory, Metastatic Colorectal Cancer

> **NCT01058655** · PHASE1,PHASE2 · COMPLETED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 56 (actual)

## Conditions studied

- Gastrointestinal Cancer

## Interventions

- **DRUG:** Everolimus
- **DRUG:** Tivozanib

## Key facts

- **NCT ID:** NCT01058655
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-02
- **Primary completion:** 2013-09
- **Final completion:** 2015-04
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2017-04-13

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01058655

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01058655, "RAD001 and AV-951 in Patients With Refractory, Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01058655. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*